Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics Chief Executive Officer Richard Nolan Townsend acquired 2,623 shares of common stock at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan, in a transaction exempt under Rule 16b-3(c) and 16b-3(d). Following this award, he directly holds 395,106 shares, including 261,349 restricted stock units.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero acquired 5,930 shares of common stock on March 13, 2026 at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan. After this transaction, he holds 131,390 shares in total, including 104,216 restricted stock units, in a transaction exempt under Rule 16b-3(c) and 16b-3(d).
Lexeo Therapeutics Chief Operating Officer Jose Manuel Otero reported an open-market sale of 3,016 shares of common stock on February 18, 2026 at a weighted average price of $6.3972 per share. The sale was made to cover tax obligations on the release of restricted stock units. After this transaction, Otero beneficially owned 125,460 shares, including 104,216 restricted stock units.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 10,173 shares of common stock at a weighted average price of $6.382 per share. According to the footnotes, this sale was made to cover tax obligations on the release of restricted stock units. Following the transaction, he directly holds 392,483 shares, which include 261,349 restricted stock units.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero corrected a prior insider trade report and detailed a small tax-related sale of shares. An earlier Form 4 had mistakenly stated that a sale to cover tax obligations occurred on August 18, 2025. This amendment clarifies that the open-market sale of 721 shares of common stock actually took place on November 18, 2025 at a weighted average price of $9.27 per share, executed in multiple trades between $9.09 and $9.37. The sale was made solely to cover tax obligations from the release of restricted stock units. After this transaction, Otero directly owns 63,476 shares of Lexeo Therapeutics common stock, including 47,733 RSUs, so his overall stake in the company remains largely unchanged.
LXEO Form 144 filing reports planned resale of 11,374 common shares tied to restricted stock vesting. The filing lists a restricted stock vesting transaction dated 02/17/2026 showing 11,374 shares as "Securities To Be Sold" and notes prior sales of 1,127 shares on 11/18/2025.
LXEO notice of proposed sale of 3,016 common shares. The filing lists 3,016 shares as "Securities To Be Sold" with an event labeled Restricted Stock Vesting dated 02/17/2026. It also shows 721 common shares sold on 11/18/2025 as a prior three‑month disposition.
LXEO submitted a Form 144 reporting the proposed sale of 3,861 common shares tied to restricted stock vesting on 02/17/2026. The filing lists Fidelity Brokerage Services LLC as a broker/firm with a trade date of 02/18/2026 and indicates NASDAQ as the market.
LXEO reported a proposed sale of 3,736 common shares via Fidelity Brokerage Services following restricted stock vesting on 02/17/2026. The filing lists a dollar figure of $23,896.58 associated with the securities and notes a prior sale of 549 shares on 11/18/2025 by Jenny R. Robertson.
LXEO affiliate files to sell 02/17/2026 a total of 4,867 common shares under a Form 144 notice. The filing states these shares arise from restricted stock vesting and were designated as compensation.
The filing also discloses 615 shares sold during the prior three months (date 11/18/2025). Timing and specific broker execution details are provided in the notice.